Mass-market twist for cystic fibrosis care, Vertex’s Trikafta stays the benchmark

Vertex’s Trikafta triple therapy remains the reference treatment for many cystic fibrosis patients, even as a new low-cost generic from Beximco Pharma undercuts its list price by more than 90 percent. What Trikafta offers, who can get it, and why it still matters for Vertex’s pipeline.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 4:10 PM ET. Details in the imprint.

Vertex Pharmaceuticals’ cystic fibrosis combination therapy Trikafta remains the company’s flagship product, anchoring its rare disease franchise even as cheaper generics begin to appear in some markets. The triple regimen of elexacaftor, tezacaftor and ivacaftor is now approved for a broad range of cystic fibrosis patients in the US and Europe, with label expansions steadily pushing eligibility down to younger age groups and a wider set of CFTR mutations. Vertex’s official CF medicines overview describes Trikafta as indicated for patients with at least one F508del mutation in the CFTR gene starting from 2 years of age in the US.

How Trikafta works and where it fits in cystic fibrosis care

Trikafta combines two CFTR correctors, elexacaftor and tezacaftor, with the CFTR potentiator ivacaftor to address the underlying protein misfolding defect that drives most cystic fibrosis cases. By improving the processing and function of the CFTR chloride channel, the regimen can raise sweat chloride levels toward normal and improve lung function as measured by percent predicted FEV1, which has translated into fewer pulmonary exacerbations in pivotal trials. In clinical studies submitted to regulators, patients receiving the fixed-dose tablets experienced rapid improvements in lung function within weeks that were sustained over longer treatment periods compared to background therapy, with reductions in exacerbation rates of around 60 percent versus placebo in some cohorts according to regulatory assessments.

For US patients, Trikafta is typically supplied as a co-pack of morning and evening tablets, dosed based on age and weight, simplifying an otherwise complex daily treatment routine for a chronic, progressive disease. Vertex’s CF portfolio strategy positions Trikafta as the default option for eligible patients with at least one F508del allele, largely replacing older doublet regimens such as Symdeko and Orkambi except in specific mutation niches or for patients who cannot tolerate the triple therapy. Real-world uptake has been strong: Vertex has reported that more than 75,000 people with cystic fibrosis worldwide are now being treated with its CFTR modulators, a figure that includes Trikafta and earlier drugs in the class and highlights the scale of its installed base. This broad penetration underpins the medicine’s status as a bestseller in the rare disease segment, with CFTR modulators contributing the bulk of the company’s annual revenue.

The commercial picture, however, is starting to change at the margins as generic competition emerges in lower-income markets outside of Vertex’s own distribution network. On June 15, 2026, Bangladesh-based Beximco Pharmaceuticals publicly handed over TRIKO, its low-cost generic version of the elexacaftor/tezacaftor/ivacaftor combination, to patients from six countries at a ceremony in Dhaka and disclosed a price of $12,750 per adult per year and $6,375 per child per year, which it framed as a 96 percent reduction from the US list price of the originator product. Reporting by The Business Standard on the TRIKO launch notes that Beximco’s generic is being positioned as an option for patients in countries where access to the branded therapy is limited by price or availability.

For Vertex, Trikafta not only drives current revenue but also funds an R&D pipeline that extends beyond cystic fibrosis into gene-editing therapies, sickle cell disease collaborations and pain programs. Despite the emergence of generics in select jurisdictions, Trikafta remains protected by a significant patent estate and regulatory exclusivity in major markets such as the US and EU, helping preserve its role as a cash generator while the company advances next-generation CFTR modulators and potential gene-based approaches aimed at patients who do not benefit from existing drugs. Investors and analysts routinely treat Trikafta’s performance as a bellwether for the health of Vertex’s CF franchise, while also watching for signs that competitive dynamics or policy changes could pressure pricing over time.

Against this backdrop, Vertex continues to trade as one of the larger US-based biotech groups on the NASDAQ. Shares of Vertex Pharmaceuticals (US92532F1003) traded on NASDAQ around the mid-$400 range in recent sessions, reflecting expectations that Trikafta and the broader CF portfolio will continue to generate substantial cash flows as the company works to diversify beyond cystic fibrosis. For more context on the company’s strategy and pipeline priorities, Vertex’s latest investor presentations and filings are available through its corporate website. MarketBeat’s coverage of Vertex Pharmaceuticals highlights how CF revenues remain central to the current investment case.

Vertex Trikafta in brief: the hard facts

• Product: Trikafta (elexacaftor/tezacaftor/ivacaftor)
• Manufacturer: Vertex Pharmaceuticals Incorporated
• Category: Flagship/Bestseller cystic fibrosis therapy
• Launch date: October 2019 (US FDA approval)
• MSRP / Price: Branded US list price in the six-figure per-year range; external reports cite generics like Beximco TRIKO at $12,750 per adult per year in some markets
• Availability: Prescription-only, through specialty pharmacies in the US and via reimbursed channels in many European markets
• Target audience: Cystic fibrosis patients aged 2 years and older with at least one F508del CFTR mutation, as specified in local labels
• Key differentiator / USP: First widely available triple CFTR modulator combination targeting the underlying cause of disease in a broad CF population

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.